As vaccines offer the best solution to control this pandemic by establishing herd immunity, it is essential to achieve substantial vaccine uptake levels across the global community ( 3). Therefore, dentists and dental team members encountered additional challenges in providing their services amid the pandemic while attempting to protect their patients and colleagues from cross-infection ( 2).įortunately, a strong global collaboration between pharmaceutical companies enabled the rapidly developing vaccines against this novel respiratory disease leading to certain vaccines receiving emergency authorization by the end of the first year of the pandemic. Dentists and dental teams need to be aware of the prevalence, severity, and prognosis of oral AEs to inform their patients and increase public confidence in vaccines.Ī wide array of clinical manifestations associated with coronavirus disease (COVID-19) have been reported within the oral cavity, including taste dysfunction, oral mucosal lesions, and salivary gland disorders ( 1). Taste-related AEs should be acknowledged in the context of the COVID-19 pandemic and the public should be adequately informed about a potential taste dysfunction after receiving the COVID-19 vaccination. The most commonly reported oral AEs were oral paraesthesia (mouth-tingling), lip swelling, and ageusia, representing various pathophysiologic pathways that remain unclear. Female sex, older age (>39 years old), primer doses, and mRNA-based COVID-19 vaccines exhibited a higher reported prevalence of oral AEs.Ĭonclusion: Within the limitations of this study, COVID-19 vaccines were found to be associated with rare oral AEs that are predominantly similar to those emerging following seasonal influenza vaccines. The distribution pattern of the most reported oral AEs was similar for both COVID-19 and seasonal influenza vaccines. The reported prevalence of oral AEs was higher in the COVID-19 vaccine group than in the seasonal influenza group. Results: Among the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) was most reported after receiving COVID-19 vaccines, followed by the swelling of lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue (0.628%), and dysgeusia (0.617%). Oral AEs reported after receiving COVID-19 vaccination (test group) and seasonal influenza vaccination (control group) were extracted and cross-tabulated to assess their relative prevalence. Methods: A retrospective analysis using the Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) and AEs involving taste and other sensations.
0 Comments
Leave a Reply. |